Regenerative Medicine News & Intelligence Hub
Pluripotent stem cell therapies are expensive, upwards of $500K–$1M per dose. Mytos has developed an automated manufacturing platform to bring that down, it's currently being used by many companies, including Aspen Neuroscience for its...
Weekly updates on regenerative medicine news, trials, and regulatory moves.
Pluripotent stem cell therapies are expensive, upwards of $500K–$1M per dose. Mytos has developed...
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell...
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a...
The trial found no significant difference in pain or function outcomes between bone marrow...
Dr. Marty Makary and Dr. Vinay Prasad publish new article in New England Journal...
NurExone's SCI candidate showed 100% gait recovery in rat models, and they're gearing up...
What appeared to be a potential stem cell breakthrough is slowly being torn apart...
What can the world learn from Japan’s regenerative medicine laws? We sat down with...
Celularity Inc. (Nasdaq: CELU), a regenerative and cellular medicine company, announced that it received recommendation letters from the FDA's Tissue Reference Group (TRG), regarding its Natalin and Acelagraft™ products confirming that each product “appears...
BioRestorative Therapies, a regenerative medicine company focused on stem cell-based therapies, has announced that the FDA has cleared its Investigational New Drug (“IND”) application for BRTX-100, a novel cell-based therapeutic engineered to...
Japan is reportedly in the final stages of approving the first induced pluripotent stem cell (iPS cell) treatment for inclusion in its national healthcare system. Approval would position Japan among the first...
South Korea's MEDIPOST, Inc., a company developing stem cell-based therapeutics, has announced the appointment of five senior executives, which they say will bring decades of expertise in biologics and cell & gene...
